ARTICLE | Company News
Hollis-Eden cancer, gastrointestinal, autoimmune news
February 9, 2009 8:00 AM UTC
Hollis-Eden will restructure and reduce headcount by about 20 (33%) to 40 to focus on its Triolex HE3286 and Apoptone HE3235 programs. Triolex is an NF-kappa B (NF-kB) inhibitor in Phase II testi...